Evidence map›Paper›PMID 42774806›Full record

ArticleMolecular therapy. Advances2026

Transduction efficiency in clinical CAR T cell products: A retrospective study at a single center.

Lipei Shao, Michaela Prochazkova, Yihua Cai, Kyu Lee Han, Kathryn Martin, Rongye Shi, Ruyan Yang, Jinxia Ma, Yanyan Zheng, Pamela Garces and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lipei ShaoCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Michaela ProchazkovaCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Yihua CaiCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Kyu Lee HanCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Kathryn MartinCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Rongye ShiCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Ruyan YangCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Jinxia MaCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Yanyan ZhengCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Pamela GarcesCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Sue-Ellen FrodighCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Victoria PhamCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Nan ZhangCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Robert P SomervilleCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
David F StroncekCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Ping JinCenter for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transduction efficiency (TE) is a key measure of CAR T cell manufacturing quality; however, its variability and relationship to the final product phenotype remain incompletely understood. In this retrospective study, we evaluated TE across 204 GMP-manufactured CAR T cell products, integrating manufacturing parameters, starting material composition, and immunophenotypic and transcriptomic profiles of final products. Multivariable linear regression and protocol-specific correlation analyses were performed to account for manufacturing-related confounding. TE variability was primarily associated with integrated manufacturing workflows and starting material composition. The CD4CD8-Prodigy-TransAct workflow was associated with higher TE compared with the CD4CD8-Bag-Dynabeads workflow, although contribution of individual manufacturing parameters could not be independently determined due to protocol-specific interdependencies. Within PBMC-based manufacturing, monocyte abundance was negatively associated with TE, suggesting protocol-dependent contributions of starting material composition. Higher TE was associated with a less differentiated T cell phenotype, including lower effector memory T cell (T

Indexed as

CAR T cellcellular therapyGMP manufacturingmanufacturing optimizationretrospective analysistransduction efficiency

Identifiers

PMID42774806
PMCPMC13594626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.